GILD Furnishes earnings results (Ex. 99.1)
Summary
Gilead Sciences, Inc. announced its third quarter 2025 financial results on October 30, 2025, via a press release (Ex. 99.1). Total revenues for increased 3% to $7.8 billion compared to the same period in 2024. Total product sales decreased 2% to $7.3 billion for the same period. - Product Sales Excluding Veklury increased 4% year-over-year to $7.1 billion. - Biktarvy Sales increased 6% year-over-year to $3.7 billion.
Why It Matters
The report highlights a 3% increase in total Q3 2025 revenues to $7.8 billion and a 4% year-over-year increase in product sales excluding Veklury to $7.1 billion, signaling continued growth in core areas. Management also noted the strongest clinical pipeline in Gilead's history and no major loss of exclusivity until 2036, positioning the company for future growth.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how GILD traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View GILD Charts on TradingViewAffiliate link
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000882095
- Filing Date
- Thursday, October 30, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive